Shanghai Cancer Center, Tencent to streamline cancer treatment with AI

Multinational investment holding conglomerate Tencent is working with the Shanghai Cancer Center to establish an AI-based, big data laboratory to streamline the cancer treatment process, according to a report by Shine, a digital news organization under Shanghai Daily.

Using AI, the entities hope to develop a clinical research and treatment platform, improve medical record management, allow for early screening for people at high risk for cancer, assign patients to appropriate experts and improve follow-up management for discharged patients, according to the report. The effort is aimed at using AI to achieve more precise medicine, better patient matching for new drug trials and a streamlined cancer treatment process.

“Many patients who come to my clinic don’t need surgery or their condition was outside my specialty, so the AI system requires patients to upload detailed information and looks for keywords, in order to avoid mismatching,” Wu Jiong, MD, PhD, a breast cancer surgeon at Shanghai Cancer Center, said in the report.

Tencent has announced several healthcare-based partnerships within the last several months. In January, the company announced a collaboration with Merck KGaA, a German-based pharmaceutical, life sciences and technology company, to leverage AI and big data to increase disease awareness and provide more accessible healthcare services. Last year, Tencent partnered with healthcare firm Medopad to train systems to use AI to better diagnose Parkinson’s disease.

To read the full report, click the link below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

One product is being pulled from the market, and the other is receiving updated instructions for use.

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?